AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18485043 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, fluoxetine, and sertraline
Number of subjects: 0
Study 18485043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (short-acting SSRI)
Number of subjects: 0
Study 18485043 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase-5 inhibitors
Number of subjects: 0
Study 18485043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetics
Number of subjects: 0
Study 18485043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (narcotic analgesic)
Number of subjects: 0
Study 15747269 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.10‐0.25 microg/kg/min) with spinal morphine (4 microg/kg) and clonidine (1 microg/kg)
Number of subjects: 40
Study 15747269 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (up to 3.5 microg/kg) with patient-controlled administration of intravenous morphine
Number of subjects: 40
Study 12060975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin I2 (5 ng/kg/min)
Number of subjects: 50
Study 12060975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (5 ng/kg/min)
Number of subjects: 50
Study 12060975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group H)
Number of subjects: 50
Study 9747741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment in patients with severe hypercalcaemia (n=51, all treated except one).
Number of subjects: 212
Study 9747741 — intervention group
Group type: COMPARATOR
Intervention: No bisphosphonate treatment in patients with severe hypercalcaemia (period 1).
Number of subjects: 212
Study 9747741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild malignancy‐associated hypercalcaemia (not treated with bisphosphonates).
Number of subjects: 212
Study 9747741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate hypercalcaemia (not treated with bisphosphonates).
Number of subjects: 212
Study 8605517 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5‐day dietary multibuffer supplement (PhosFuel)
Number of subjects: 20
Study 2664173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 46
Study 2664173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 788743 — intervention group
Group type: EXPERIMENTAL
Intervention: L-noradrenaline infusion
Number of subjects: 17
Study 788743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 17
Study 788743 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 17
Study 31385854 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 51
Study 31385854 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 51
Study 29055668 — intervention group
Group type: COMPARATOR
Intervention: Single isocaloric liquid meal (L-SM) 600-kcal
Number of subjects: 32
Study 29055668 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal (S-SM) 600-kcal
Number of subjects: 32
Study 29055668 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 200-kcal minimeals (S)
Number of subjects: 32
Study 29055668 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric pouch emptying
Number of subjects: 32
Study 26658459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and food safety education intervention (lectures 0.5 hour per week for two semesters)
Number of subjects: 478
Study 26658459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 478
Study 23290927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonar-assisted search
Number of subjects: 10
Study 23290927 — intervention group
Group type: COMPARATOR
Intervention: Standard search pattern
Number of subjects: 10
Study 21292602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise program for 16 weeks, three times per week, at 60 to 80 percent of the maximum heart rate.
Number of subjects: 40
Study 18726150 — intervention group
Group type: EXPERIMENTAL
Intervention: Faux pas task (an advanced test of theory of mind)
Number of subjects: 0
Study 16759923 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis (menstrual phase)
Number of subjects: 35
Study 16759923 — intervention group
Group type: COMPARATOR
Intervention: Control (normal pelvis)
Number of subjects: 35
Study 15099277 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0-2.5)
Number of subjects: 0
Study 15099277 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.8-4.2)
Number of subjects: 0
Study 15099277 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 160 mg d(‐1)
Number of subjects: 0
Study 15099277 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg d(‐1)
Number of subjects: 0
Study 15099277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Aspirin + Warfarin)
Number of subjects: 0
Study 11708708 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder and hip flexor training (n = 14)
Number of subjects: 28
Study 11708708 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group (n = 12)
Number of subjects: 28
Study 9803197 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy (diuretics or beta-adrenergic blockers)
Number of subjects: 0
Study 9803197 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modifications (not specified in detail)
Number of subjects: 0
Study 7972630 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 7972630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 0
Study 7972630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7972630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 2701002 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable thermoplasticized gutta-percha (Ultrafil)
Number of subjects: 100
Study 2701002 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation technique (Control)
Number of subjects: 100
Study 2701002 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with sealer
Number of subjects: 100
Study 4558249 — intervention group
Group type: EXPERIMENTAL
Intervention: FTA-ABS test
Number of subjects: 1922
Study 4558249 — intervention group
Group type: COMPARATOR
Intervention: RPCFT and automated reagin test
Number of subjects: 1922
Study 4558249 — intervention group
Group type: COMPARATOR
Intervention: Cardiolipin WR
Number of subjects: 1922
Study 30653851 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone/Pioglitazone/Metformin (SPIOMET), n = 24
Number of subjects: 51
Study 30653851 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive (OC), n = 27
Number of subjects: 51
Study 30653851 — intervention group
Group type: COMPARATOR
Intervention: Controls, n = 12
Number of subjects: 51
Study 28985722 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral card with contact details of services providing assistance and tips to increase safety behaviour
Number of subjects: 189
Study 28985722 — intervention group
Group type: COMPARATOR
Intervention: Thank you card
Number of subjects: 189
Study 24969566 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g/day Inulin-type fructans (ITF) for 3 months
Number of subjects: 30
Study 24969566 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo) for 3 months
Number of subjects: 30
Study 23036570 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-domain optical coherence tomography
Number of subjects: 487
Study 23036570 — intervention group
Group type: EXPERIMENTAL
Intervention: Average RNFL loss
Number of subjects: 487
Study 23036570 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior RNFL loss
Number of subjects: 487
Study 23036570 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field index improvement
Number of subjects: 487
Study 23036570 — intervention group
Group type: EXPERIMENTAL
Intervention: RNFL improvement
Number of subjects: 487
Study 21515997 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma massage using a mixture of lemon, lavender, rosemary, and cyprus oil, given 5 days a week for 4 weeks
Number of subjects: 38
Study 21515997 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian massage at 9 acupoints influencing intestinal functions, given 5 days a week for 4 weeks
Number of subjects: 38
Study 18025439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus autologous stem-cell transplantation (HDCT)
Number of subjects: 224
Study 18025439 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 224
Study 17049332 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan phakic intraocular lens (PIOL)
Number of subjects: 31
Study 17049332 — intervention group
Group type: EXPERIMENTAL
Intervention: Artiflex phakic intraocular lens (PIOL)
Number of subjects: 31
Study 11979994 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for unstable coronary artery disease according to European Society of Cardiology guidelines
Number of subjects: 0
Study 10086546 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg every 6 hours for 5 days)
Number of subjects: 0
Study 10086546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7668913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 195
Study 7668913 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep coma (scoring 0-2)
Number of subjects: 195
Study 7668913 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anaemia (haematocrit < 18%)
Number of subjects: 195
Study 7668913 — intervention group
Group type: EXPERIMENTAL
Intervention: Asexual parasite counts
Number of subjects: 195
Study 1754611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white-light treatment (2,500 lux)
Number of subjects: 42
Study 1754611 — intervention group
Group type: COMPARATOR
Intervention: Dim red-light treatment (50 lux)
Number of subjects: 42
Study 7031215 — intervention group
Group type: EXPERIMENTAL
Intervention: Three days of nitrofurantoin macrocrystals therapy
Number of subjects: 49
Study 7031215 — intervention group
Group type: COMPARATOR
Intervention: Ten days of nitrofurantoin macrocrystals therapy
Number of subjects: 49
Study 6094104 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 40 mg/day)
Number of subjects: 15
Study 6094104 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus propranolol (50 mg hydrochlorothiazide plus 80 to 240 mg propranolol/day)
Number of subjects: 15
Study 31634898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipredictor nomogram combining neuroimaging features, CSF biomarkers, and clinical assessments.
Number of subjects: 290
Study 31634898 — intervention group
Group type: COMPARATOR
Intervention: Nomogram using either Rad-sig or Aβ concentration as individual predictors.
Number of subjects: 290
Study 29933749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) alone
Number of subjects: 0
Study 29933749 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) combined with high-dose aspirin
Number of subjects: 0
Study 27111004 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computerized tutorial
Number of subjects: 63
Study 27111004 — intervention group
Group type: COMPARATOR
Intervention: 3D images without computerized tutorial
Number of subjects: 63
Study 24480335 — intervention group
Group type: EXPERIMENTAL
Intervention: Active somatosensory stimulation + task-specific training (TST)
Number of subjects: 33
Study 24480335 — intervention group
Group type: COMPARATOR
Intervention: Sham somatosensory stimulation + task-specific training (TST)
Number of subjects: 33
Study 23194032 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammographic screening starting at age 40
Number of subjects: 0
Study 19779037 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-microg/kg bolus followed by a 2-microg/kg/min infusion
Number of subjects: 22
Study 19779037 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microg/kg bolus followed by a 4-microg/kg/min infusion
Number of subjects: 22
Study 18822490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 4 g daily (Group 1)
Number of subjects: 75
Study 18822490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal paracetamol in equipotential dose (Group 2)
Number of subjects: 75
Study 18822490 — intervention group
Group type: COMPARATOR
Intervention: No paracetamol (Group 3)
Number of subjects: 75
Study 15677777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (monotherapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus sulfonylurea (combination therapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin (combination therapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: COMPARATOR
Intervention: Metformin (monotherapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (monotherapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus sulfonylurea (combination therapy)
Number of subjects: 940
Study 15677777 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide plus metformin (combination therapy)
Number of subjects: 940
Study 11788698 — intervention group
Group type: EXPERIMENTAL
Intervention: StatLock securement
Number of subjects: 170
Study 11788698 — intervention group
Group type: COMPARATOR
Intervention: Suture securement
Number of subjects: 170
Study 10077377 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based St. Thomas' cardioplegia
Number of subjects: 50
Study 10077377 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid St. Thomas' cardioplegia
Number of subjects: 50
Study 9238566 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2248328 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine (2% dilution in castor oil)
Number of subjects: 11
Study 2248328 — intervention group
Group type: COMPARATOR
Intervention: Castor oil alone (control)
Number of subjects: 11
Study 6988713 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 258
Study 6988713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 258
Study 30027388 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm handoff (patient connected to quitline at bedside)
Number of subjects: 1054
Study 30027388 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratings of the tobacco treatment care transition
Number of subjects: 1054
Study 30027388 — intervention group
Group type: EXPERIMENTAL
Intervention: Being older
Number of subjects: 1054
Study 30027388 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher transition of care ratings
Number of subjects: 1054
Study 30027388 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cessation medication post-discharge
Number of subjects: 1054
Study 30027388 — intervention group
Group type: COMPARATOR
Intervention: Fax referral (referral faxed to proactive quitline)
Number of subjects: 1054
Study 26924303 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg quercetin
Number of subjects: 22
Study 26924303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26506968 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration plus hemoperfusion (HVHF&HP)
Number of subjects: 20
Study 26506968 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (control group)
Number of subjects: 20
Study 22890639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (5 mg/h)
Number of subjects: 1157
Study 22890639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 21221773 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg daily for 12 months
Number of subjects: 98
Study 21221773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 98
Study 19369178 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus Methotrexate (MTX)
Number of subjects: 47
Study 19369178 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 47
Study 17534968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and house dust mite avoidance during the first 5 years of life
Number of subjects: 219
Study 14988452 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (S)
Number of subjects: 14
Study 14988452 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (SN)
Number of subjects: 14
Study 14988452 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of sterols and stanols (SSN)
Number of subjects: 14
Study 14988452 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch (control)
Number of subjects: 14
Study 11956614 — intervention group
Group type: EXPERIMENTAL
Intervention: Softcyte
Number of subjects: 315
Study 11956614 — intervention group
Group type: COMPARATOR
Intervention: Endocyte
Number of subjects: 315
Study 9971914 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric-coated formulation A
Number of subjects: 0
Study 9971914 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole enteric-coated formulation B
Number of subjects: 0
Study 7752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running (DHR) at -10% grade for 60 min
Number of subjects: 10
Study 7752863 — intervention group
Group type: COMPARATOR
Intervention: Level running (LR) at 0% grade for 60 min
Number of subjects: 10
Study 2288396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol (0.5 mg administered by a jet nebulizer twice daily for 2 months)
Number of subjects: 20
Study 7275468 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fasting
Number of subjects: 14
Study 7275468 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD)
Number of subjects: 14
Study 30116543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 644
Study 30116543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study 27196390 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster family intervention (FFI)
Number of subjects: 123
Study 27196390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 123
Study 25007695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Group
Number of subjects: 200
Study 25007695 — intervention group
Group type: COMPARATOR
Intervention: Clinical Group
Number of subjects: 200
Study 22362918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 66
Study 22362918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20185036 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection (DP)
Number of subjects: 626
Study 20185036 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 626
Study 17350856 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ACEI or ARB use (175 patients)
Number of subjects: 338
Study 17350856 — intervention group
Group type: COMPARATOR
Intervention: No preoperative ACEI or ARB use (163 patients)
Number of subjects: 338
Study 16298736 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) at 1200 or 1800 mg/day
Number of subjects: 45
Study 16298736 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration at 2 l/m for 18 h
Number of subjects: 45
Study 9676460 — intervention group
Group type: EXPERIMENTAL
Intervention: HASTE MRI
Number of subjects: 72
Study 9676460 — intervention group
Group type: COMPARATOR
Intervention: Sonography
Number of subjects: 72
Study 8034815 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal/stressful condition
Number of subjects: 57
Study 8034815 — intervention group
Group type: EXPERIMENTAL
Intervention: Written/stressful condition
Number of subjects: 57
Study 8034815 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal/stressful group
Number of subjects: 57
Study 8034815 — intervention group
Group type: COMPARATOR
Intervention: Written/trivial control group
Number of subjects: 57
Study 2723355 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia started at the beginning of induction
Number of subjects: 88
Study 2723355 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia started when labor became active
Number of subjects: 88
Study 2723355 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia timing in primiparous patients
Number of subjects: 88
Study 2723355 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia timing in multiparous patients
Number of subjects: 88
Study 30080128 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational and reminder text messages sent twice a week for 3 months
Number of subjects: 42
Study 30080128 — intervention group
Group type: COMPARATOR
Intervention: No text messages (control group)
Number of subjects: 42
Study 27988868 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month weight loss intervention
Number of subjects: 14
Study 25741153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) after endoscopic papillary balloon dilatation (EPBD)
Number of subjects: 218
Study 25741153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) after endoscopic sphincterotomy (EST)
Number of subjects: 218
Study 25741153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) without any procedure
Number of subjects: 218
Study 25741153 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) after EPBD
Number of subjects: 218
Study 25741153 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) after EST
Number of subjects: 218
Study 25741153 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (non-ENBD) without any procedure
Number of subjects: 218